How proteomics is shaping pharma strategies
23 Feb 2024
In this video from Olink®, experts discuss how proteomics is shaping pharmaceutical strategies. They describe the integration of proteomics into drug discovery and development, highlighting the importance of proteomic biomarkers for clinical trials and precision medicine. They also explore the challenges associated with proteomic analysis and the need for standardization and validation of assays and technologies.
About the company
Olink Proteomics
Olink Proteomics is a Swedish company dedicated to innovation, quality, rigor and transparency, providing outstanding products and services for human protein biomarker discovery. Olink panels for precision proteomics help scientists make research decisions more quickly and confidently through robust, multiplex biomarker analysis. Its high-quality multiplex immunoassay panels help bring new insights into disease processes, improve disease detection, and contribute to a better understanding of biology.
Based on the pioneering research of Professor Ulf Landegren and his group at Uppsala University, Sweden, Olink was founded in 2004, The company has a successful history of developing molecular technologies, with a broad IP portfolio. Many of these have been commercialized through out-licensing to industry-leading partners such as Affymetrix, Life Technologies, and through the spin-out companies Qlinea and Halo Genomics (now part of Agilent). Olink sold its highly successful Duolink product line for in situ detection of proteins to Sigma-Aldrich in 2015.
Following a company reorganization in April, 2016, Olink Proteomics is focusing entirely on developing and expanding its platform of high-multiplex immunoassay panels for protein biomarker discovery.
